Hierarchy of clinical manifestations in SAVI N153S and V154M mouse models
Author(s) -
Mona Motwani,
Sudesh Pawaria,
Jennifer Bernier,
Stephanie Moses,
Kate L. Henry,
Terry Fang,
Linda C. Burkly,
Ann MarshakRothstein,
Katherine A. Fitzgerald
Publication year - 2019
Publication title -
proceedings of the national academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.011
H-Index - 771
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.1818281116
Subject(s) - biology , sting , immune system , inflammation , immunology , innate immune system , fibrosis , mutation , pulmonary fibrosis , disease , mutant , gene , cancer research , genetics , medicine , pathology , engineering , aerospace engineering
Significance STING is a key driver of monogenic interferonopathies that include STING-associated vasculopathy with onset in infancy (SAVI). Defining the molecular mechanisms and the contribution of individual cell types to disease could unveil new therapeutic targets for management of SAVI and related autoimmune diseases. Here we compare and contrast murine models representative of the two most common mutations and identify a hierarchy of lymphoid abnormalities that depend on T cell-intrinsic expression of the SAVI mutation. Although clinical manifestations result from hyperactivation of STING, they occur independently of type I interferon and necroptosis. These murine models facilitate a dissection of the role of STING in specific tissues and provide tools for evaluating STING inhibitors for the treatment of SAVI patients.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom